Scientific Highlights

We congratulate Dr. Chiara Favaretto for the excellent research work she did during her time at the Center for Radiopharmaceutical Sciences.

The translational project "PROGNOSTICS", proposed by a consortium led by Prof. Roger Schibli, received CHF 2 million funding from the PHRT initiative of the ETH Domain(https://www.sfa-phrt.ch/two-clinical-trial-projects-launched-transforming-clinical-care-with-eth-technologies/). The study is being conducted with the Co-applicants Prof. Dr. med. Damian Wild at the University Hospital Basel and Prof. Dr. Nicola Aceto of the ETHZ. The consortium will test a new radiopharmaceutical developed at the Center for Radiopharmaceutical Sciences in 36 patients with advanced prostate cancer.

Professor Dr. Cristina Müller.

Prof. Roger Schibli was awarded an Honorary Fellow of the Society of Radiopharmaceutical Sciences (SRS) “in recognition of substantial contribution to the SRS”.

Prof. Roger Schibli (third person from the left).

Dr. Francesca Borgna, former Marie Curie Fellow at the Center for Radiopharmaceutical Sciences awarded by the Institute of Pharmaceutical Sciences in 2022 and gave the IPW Young Scientist lecture entitled: "Combination of Terbium-161 with Somatostatin Receptor Antagonists: a Potential Paradigm Shift for the Treatment of Neuroendocrine Neoplasm.

Rahel Wallimann, PhD student in the “Nuclide Chemistry Group”, received the first prize (AKB Foundation) of the SAPhW Poster Award at the Swiss Pharma Science Day 2022.

Chiara Favaretto, PhD student in the “Radionuclide Development” group at the Center for Radiopharmaceutical Sciences, received the NMB/Eckelman Young Investigator Award for the abstract entitled: “Production and radiochemical separation of terbium-155 from enriched gadolinium target material and its preliminary application in SPECT imaging”, presented at the International Symposium on Radiopharmaceutical Sciences (iSRS 2022).

Luisa Deberle, PhD student in the “Nuclide Chemistry Group” received the price for the best oral presentation

Viviane Tschan received this year’s Marie-Curie Award for a new concept of radioligand therapy of prostate cancer.

PSI is engaging in public outreach at a major event in Zürich, the "Scientifica" Science Days September 4 and 5.

European Society for Molecular Imaging - ESMI

The ESMI represents and advocates IMAGING SCIENCE

The ESMI is providing an international, interdisciplinary platform for knowledge exchange in the field covering basic sciences, translational aspects as well as clinical applications.

Research Division Biology and Chemistry (BIO), Folate Receptor Targeting Group, Head Cristina Müller. In recent years, implementation of 68Ga-radiometalated peptides for PET imaging of cancer has attracted the attention of clinicians. Herein, we propose the use of 44Sc (half-life = 3.97 h, average β+ energy [Eβ+av] = 632 keV) as a valuable alternative to 68Ga (half-life = 68 min, Eβ+av = 830 keV) for imaging and dosimetry before 177Lu-based radionuclide therapy.